
|Videos|March 25, 2021
Continuing the Success Story With TRK Inhibitors
Author(s)David S. Hong, MD
David S. Hong, MD, of the University of Texas MD Anderson Cancer Center, reacts to the growing interest around identifying NTRK gene fusions in various solid tumor types and treating appropriate patients with oral TRK inhibitors.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5






































